XERIS BIOPHARMA HOLDINGS, INC. Variable Lease, Cost
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Variable Lease, Cost of $1.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. variable lease, cost for the quarter ending 2026-06-30 was $1.05M, a 8.11% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. variable lease, cost for the quarter ending 2026-03-31 was $912.00K, a 6.46% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. variable lease, cost for the quarter ending 2025-12-31 was $980.00K, a 8.77% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. variable lease, cost for the quarter ending 2025-09-30 was $986.00K, a 109.34% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. variable lease, cost for fiscal 2025 was $3.92M, a 102.01% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. variable lease, cost for fiscal 2024 was $1.94M, a 60.43% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. variable lease, cost for fiscal 2023 was $1.21M, a 10.72% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. variable lease, cost for fiscal 2022 was $1.09M.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.05M 10-Q · filed 2026-08-06 | $1.97M 10-Q · filed 2026-08-06 | $2.94M derived: sum of 3 quarters · filed 2026-08-06 | $3.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $912.00K 10-Q · filed 2026-05-07 | $1.89M derived: sum of 2 quarters · filed 2026-05-07 | $2.88M derived: sum of 3 quarters · filed 2026-05-07 | $3.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $980.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.97M derived: sum of 2 quarters · filed 2026-03-02 | $2.94M derived: sum of 3 quarters · filed 2026-08-06 | $3.92M 10-K · filed 2026-03-02 |
| 2025-09-30 | $986.00K 10-Q · filed 2025-11-06 | $1.96M derived: sum of 2 quarters · filed 2026-08-06 | $2.94M 10-Q · filed 2025-11-06 | $3.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $974.00K 10-Q · filed 2026-08-06 | $1.95M 10-Q · filed 2026-08-06 | $2.85M derived: sum of 3 quarters · filed 2026-08-06 | $3.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $975.00K 10-Q · filed 2026-05-07 | $1.88M derived: sum of 2 quarters · filed 2026-05-07 | $2.35M derived: sum of 3 quarters · filed 2026-05-07 | $2.67M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $901.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.37M derived: sum of 2 quarters · filed 2026-03-02 | $1.70M derived: sum of 3 quarters · filed 2026-03-02 | $1.94M 10-K · filed 2026-03-02 |
| 2024-09-30 | $471.00K 10-Q · filed 2025-11-06 | $796.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.04M 10-Q · filed 2025-11-06 | $1.31M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $325.00K 10-Q · filed 2025-08-07 | $566.00K 10-Q · filed 2025-08-07 | $836.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.12M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $241.00K 10-Q · filed 2025-05-08 | $511.00K derived: sum of 2 quarters · filed 2026-03-02 | $797.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.10M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $556.00K derived: sum of 2 quarters · filed 2026-03-02 | $858.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.21M 10-K · filed 2026-03-02 |
| 2023-09-30 | $286.00K 10-Q · filed 2024-11-08 | $588.00K derived: sum of 2 quarters · filed 2024-11-08 | $938.00K 10-Q · filed 2024-11-08 | $1.38M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $302.00K 10-Q · filed 2024-08-08 | $652.00K 10-Q · filed 2024-08-08 | $1.09M derived: sum of 3 quarters · filed 2025-03-06 | $1.30M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $350.00K 10-Q · filed 2024-05-09 | $789.00K derived: sum of 2 quarters · filed 2025-03-06 | $1.00M derived: sum of 3 quarters · filed 2025-03-06 | $1.22M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $439.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $651.00K derived: sum of 2 quarters · filed 2025-03-06 | $866.00K derived: sum of 3 quarters · filed 2025-03-06 | $1.09M 10-K · filed 2025-03-06 |
| 2022-09-30 | $212.00K 10-Q · filed 2023-11-09 | $427.00K derived: sum of 2 quarters · filed 2023-11-09 | $652.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $215.00K 10-Q · filed 2023-08-08 | $440.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $225.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |